Technology | Enterprise Imaging | March 20, 2017

Agfa HealthCare Releases Newest Version of Enterprise Imaging for Cardiology at ACC.17

Company also displayed early concept for collaboration with IBM Watson Health for automated structure reporting based on natural language processing and cognitive analytics

Agfa HealthCare, Enterprise Imaging for Cardiology, ACC.17, IBM Watson Health

March 20, 2017 — Agfa HealthCare announced the release a new version of its Enterprise Imaging for Cardiology platform at the American College of Cardiology ACC.17 expo, March 17-19 in Washington, D.C. Customer-driven enhancements include new structured reporting modules for congenital echocardiology and nuclear cardiology.

The suite is part of the Enterprise Imaging converged platform, which offers a care-centric workflow that is standards-based, improves interoperability and enables a comprehensive patient health record across departments within a single facility or between multiple facilities.

With Enterprise Imaging for Cardiology, cardiologists have a robust environment providing a single point of access to patient information from different sources. They can quickly retrieve a patient's complete cardiology file, generate a report and distribute it, all during one session, even from a remote location. Images, reports and relevant, sophisticated toolkits are supported by the task-based workflow that aligns with and supports their clinical workflow.

The new features provide support for congenital echocardiology and nuclear cardiology, deeply integrated into the Enterprise Imaging platform.

At ACC.17, Agfa HealthCare also showed an early concept for automated structured reporting based on natural language processing (NLP) and cognitive analytics, a work in progress in collaboration with IBM Watson Health. This collaboration illustrated how clinicians may be able to use normal dictation methods for reporting and still achieve structured report, as well as structured data using a natural language processing and cognition-based algorithm powered by IBM Watson, to convert dictated reports into structured data.

For more information: www.agfahealthcare.com

Related Content

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies| March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low do
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals| March 22, 2017
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of...
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers| March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies
Feature | ACC| March 22, 2017
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presente
Toshiba, Aquilion One CT, model-based iterative reconstruction, MBIR, ACC 2017, FIRST, RSNA 2017
News | Computed Tomography (CT)| March 21, 2017
March 21, 2017 — Toshiba Medical demonstrated its Forward projected model-based Iterative Reconstruction SoluTion (FI
RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology| March 21, 2017
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clo
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
Overlay Init